Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone Dipropionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 0.98 |
| ▸ | PGR | P06401 | 5/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.98 |
| ▸ | MAPT | P10636 | 2/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.98 |
| ▸ | DRD2 | P14416 | 1/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.83 |
| ▸ | USP2 | O75604 | 5/20 | 0.83 |
| ▸ | LMNA | P02545 | 3/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.83 |
| ▸ | MLNR | O43193 | 1/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.83 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.83 |
| ▸ | PPARG | P37231 | 1/20 | 0.83 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.79 |
| ▸ | CNR1 | P21554 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone Dipropionate SCHEMBL1868583 | 1.00 | NR3C1 (0.98) | NR3C1PGRNR1I2MAPTADORA3 | |
| Dexamethasone Dipropionate SCHEMBL43107 | 0.99 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL13028946 | 0.99 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL4566 | 0.99 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL10013893 | 0.99 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL20097870 | 0.99 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL10014288 | 0.99 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL11429865 | 0.99 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL9768468 | 0.99 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL7519 | 0.99 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11969432-B2 | Pharmaceutical composition and use thereof | BARNAS, ARIAN JANKUR CAN (AT) | 2024-04-30 | — | — | US | claimed |
| EP-1512008-A4 | USE OF CORTICOTROPH-DERIVED GLYCOPROTEIN HORMONE TO TREAT INFLAMMATION AND POTENTIATE GLUCOCORTICOID ACTION | ZYMOGENETICS INC (US) | 2007-02-14 | — | — | EP | claimed |
| US-20070010446-A1 | METHODS FOR TREATING INFLAMMATION USING THYROID STIMULATING HORMONE | ZYMOGENETICS, INC. | 2007-01-11 | — | — | US | claimed |
| EP-1706138-A2 | METHODS FOR TREATING INFLAMMATION USING THYROID STIMULATING HORMONE | ZymoGenetics, Inc. (US) | 2006-10-04 | — | — | EP | claimed |
| US-20050171017-A1 | Methods for treating inflammation using thyroid stimulating hormone | ZYMOGENETICS, INC. | 2005-08-04 | — | — | US | claimed |
| WO-2005056046-A2 | METHODS FOR TREATING INFLAMMATION USING THYROID STIMULATING HORMONE | ZYMOGENETICS, INC. (US) | 2005-06-23 | — | — | WO | claimed |
| EP-1512008-A1 | USE OF CORTICOTROPH-DERIVED GLYCOPROTEIN HORMONE TO TREAT INFLAMMATION AND POTENTIATE GLUCOCORTICOID ACTION | ZymoGenetics, Inc. (US) | 2005-03-09 | — | — | EP | claimed |
| US-20040138113-A1 | Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action | ZYMOGENETICS, INC. | 2004-07-15 | — | — | US | claimed |
| WO-2003104807-A1 | USE OF CORTICOTROPH-DERIVED GLYCOPROTEIN HORMONE TO TREAT INFLAMMATION AND POTENTIATE GLUCOCORTICOID ACTION | ZYMOGENETICS, INC. (US) | 2003-12-18 | — | — | WO | claimed |
| WO-2000040269-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF DISEASED TISSUES | LEE CLARENCE C (US) | 2000-07-13 | — | — | WO | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2026-05-28 | — | — | US | disclosed |
| US-12630603-B2 | Chimeric antigen receptor T cell therapy | KITE PHARMA, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260125449-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| CN-1232397-A | Use of H+, K+-ATPase inhibitor in treatment of nasal polyps | ASTRA AB (SE) | 1999-10-20 | — | — | CN | disclosed |
| US-5723145-A | MULTILAYER ELEMENT FOR TRANSDERMAL DRUG DELIVERY | TAKIRON CO., LTD. (JP) | 1998-03-03 | — | — | US | disclosed |
| CN-1115964-A | Percutaneous absorption preparation | TAKIRON CO (JP) | 1996-01-31 | — | — | CN | disclosed |
| EP-0671176-A1 | PERCUTANEOUSLY ABSORBABLE PREPARATION | TAKIRON CO. LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1992013547-A1 | DRUG DELIVERY COMPOSITION AND METHOD OF USING THE SAME | EATON ALEXANDER MELLON (US) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | LIPA, NSF, SLC26A3 | NR3C1 3525/4885PGR 1708/4885NR1I2 3803/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | NR3C1 2701/4885PGR 334/4885NR1I2 2115/4885 |
| US-20260125449-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | MALT1, BCL9, ICOS | NR3C1 2836/4885PGR 1102/4885NR1I2 2709/4885 |
| US-12630603-B2 | Chimeric antigen receptor T cell therapy | CD4, ICOS, CD69 | NR3C1 1425/4885PGR 1005/4885NR1I2 1281/4885 |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | MYH10, PDGFA, MPL | NR3C1 4364/4885PGR 157/4885NR1I2 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.